LobbyingData.com Logo

Xenonics Inc (XENE) all U.S. Lobbying: all historical lobbying contracts, government bills & agencies, and critical issues lobbied on.

$99.95

Discover Xenonics Inc’s lobbying activities with our comprehensive dataset, offering insights on spending, bills, and issues from 1999-present. Analyze data by company, lobbyist, issue, and more through our intelligently crafted data design. Dataset updated weekly.

Description

Using our intelligently designed and intuitive dataset, you can quickly understand how Xenonics Inc (XENE) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.

Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.

For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.

Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.

Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:

1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.

2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.

3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).

4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.

5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).

6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).

7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).

Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].

Frequently Asked Questions

What is Xenonics Inc (XENE) lobbying for?

Summary of lobbying data:

Xenonics Inc hired Venable Llp as their lobbying firm and lobbied on general issues of Copyright/Patent/Trademark, Taxation/Internal Revenue Code, and Health Issues over the 10 most recent lobbying contracts they submitted. Their specific issues of lobbying include Ensuring Patient Access and Effective Drug Enforcement Act of 2015, Medicaid Generic Drug Price Fairness Act, Protect Medical Innovation Act of 2015, incentives for life sciences research, tax treatment of inverted companies, tax issues in mergers and acquisitions of US firms, America Invents Act, patent settlements, misuse of the inter pares review process, bioequivalence and related administrative procedures, and prescription drug abuse. They also lobbied on government agencies of Senate and House of Representatives.

One could infer that Xenonics Inc is lobbying on these issues in order to influence policies and regulations that affect their business interests in the pharmaceutical industry. The issues they lobbied on such as patent reform, FDA approvals of new drugs and generic drugs, incentives for tamper-resistant formulations, Medicare Part D rebates, and opioid abuse legislation suggest that they are focused on protecting their investments in research and development, ensuring access and affordability of their drugs, and staying profitable in a competitive market. Additionally, their lobbying on tax issues in mergers and acquisitions of US firms and tax treatment of inverted companies suggests that they are trying to advocate for policies that favor their financial interests.

Subscribe To Our Newsletter

gain actionable insights from our alternative data

More to explore